Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (ADCT) is a commercial-stage biopharmaceutical leader pioneering antibody drug conjugates (ADCs) for advanced oncology treatments. This page serves as the definitive source for all company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases and news articles detailing ADCT's progress in developing targeted therapies for hematologic malignancies and solid tumors. Our collection includes updates on product commercialization, clinical study results, and research collaborations, providing critical insights into the company's scientific and operational trajectory.
Key content categories cover quarterly financial results, FDA/EMA regulatory filings, and advancements in ADC technology. Bookmark this page to stay informed about ADCT's innovations in precision oncology and its growing impact on cancer treatment paradigms.
ADC Therapeutics SA, listed as NYSE: ADCT, will have its CEO, Ameet Mallik, participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. The presentation will be live-streamed on the company's website, with a replay available for 30 days.
ADC Therapeutics SA (NYSE: ADCT) has announced an underwritten offering of 13,411,912 common shares at $4.900 per share and pre-funded warrants to purchase 8,163,265 common shares at $4.812 per pre-funded warrant, expecting to raise approximately $105.0 million. The offering is set to close on May 8, 2024, with Jefferies, Guggenheim Securities, and Cantor as joint book-running managers. A registration statement has been filed with the SEC, and more details can be found on the SEC's website.
ADC Therapeutics reported a net sales of $17.8 million for ZYNLONTA® in 1Q 2024 with total operating expenses decreasing 25%; LOTIS-7 dose escalation completed and 2L+ DLBCL expansion initiated; MZL IIT Phase 2 data showed 13 CR and 1 PR patients; next-generation ADC platform showcased promising preclinical data in NaPi2b, Claudin-6, PSMA, and ASCT2; cash and cash equivalents at $234.3 million, expecting runway until Q4 2025.
ADC Therapeutics announced initial data from an investigator-initiated Phase 2 clinical trial of ZYNLONTA® in patients with relapsed/refractory marginal zone lymphoma. Of the 15 patients evaluated, 13 achieved a complete response and one achieved a partial response. The drug was well-tolerated, with two patient discontinuations due to toxicity, both remaining in complete response. The study was presented at the Lymphoma Research Foundation's 2024 Marginal Zone Lymphoma Scientific Workshop.
ADC Therapeutics SA announced grants of options to purchase 147,600 common shares to four new employees on May 1, 2024, as part of an Inducement Plan. The grants were approved by the Compensation Committee to motivate employees to perform at their best. The shares will vest over four years, contingent on continued employment.
ADC Therapeutics SA (NYSE: ADCT) will host a conference call and webcast on May 6, 2024, to report Q1 2024 financial results and provide pipeline updates. Registrants can access the call via dial-in or webcast. The company aims to share recent progress on key pipeline catalysts.
FAQ
What is the current stock price of Adc Therapeutics Sa (ADCT)?
What is the market cap of Adc Therapeutics Sa (ADCT)?
